The clinical success rate for developing an analgesic is 2% - five times lower than other therapeutic areas.
Current treatment options are limited with only 1 in 8 people receiving satisfactory pain relief with standard of care.
We have to change how we conduct R&D and link research to specific pain conditions to create precision-analgesics™.
Keys to Analgesic Innovation
(takes you to LinkedIn articles)
Creating new approaches to develop precision-analgesics™